Kohlberg Kravis Roberts

Kohlberg Kravis Roberts is a prominent global investment firm that specializes in managing a diverse range of alternative asset classes, including private equity, energy, infrastructure, real estate, and credit, as well as hedge funds through strategic partnerships. Founded in 1976, the firm focuses on generating attractive investment returns by employing a disciplined and patient investment approach. KKR is committed to driving growth and value creation in its portfolio companies while aligning its interests with those of its investment partners. The firm also provides comprehensive human resources services to enhance operational effectiveness. With a presence in multiple countries, including India and Japan, KKR continues to leverage its extensive expertise and industry knowledge to deliver value across its investment strategies.

Taski Ahmed

Principal, KKR Prisma

Mustapha Angwa

CEO

Anne Arlinghaus

Managing Director

Joe Bae

Co-President and Co-COO

David Biener

VP Finance

Todd Builione

Member, President of KKR Credit

Jim Burns

Partner

Daniel Celeghin

Managing Director, Client and Partner Group

Spencer Chavez

Principal

Mukul Chawla

Partner, Head of Asia Pacific Growth Equity

Steve Codispoti

Director, Finance

Benjamin Conner

Managing Director

Kendra Decious

Director, Finance

Patrick Devine

Director

Brian Dillard

Partner and Head of Asia Credit

Brandon Donnenfeld

Director

Jamison Ely

Director

Mark Ennis

Director

Len Fliegel

Director

Marco Fontana

Managing Director

Brandon Freiman

Partner, Head of North American Infrastructure

Philipp Freise

Co-Head of European Private Equity

Terence Gallagher

Managing Director

Travers Garvin

Director, Public Affairs

Felix Gernburd

Managing Director

Alan Grant

Principal, KKR Capstone

Elizabeth Hammond

Managing Director

Chris Harrington

Partner

Erich Heintzen

Director

Jill Henn

Managing Director, Human Capital

Sota Horiuchi

Principal, Private Equity

Jeff Van Horn

Managing Director, Credit

Paul Horwood

CFO, European Operations

Mark Hunt

Director, Capital Management Group

Johannes P. Huth

Managing Director and Head of KKR EMEA

Hisao Iijima

Principal, Private Equity

Gary H. Jacobs

Managing Director, Capital Management Group

Zhen Ji

Managing Director, China

Franziska Kayser

Managing Director

Kazuyuki Kido

Managing Director

Philip Kim

Managing Director

Thomas Kim

Managing Director and Global Risk Manager

Daan Knottenbelt

Partner

Rie Koike

Principal, Client and Partner Group

Joan Lacagnina

Managing Director, Finance

Jeremiah Lane

Principal

Dashiell Lane

Director, Energy and Infrastructure

David Lang

Partner

Joshua Lederman

Principal and Associate

Elissa Leechawengwongs

Principal, Private Equity

Vincent Letteri

Managing Director, TMT Growth Equity

Robert Lewin

Partner

Xiang Li

Managing Director, Private Equity

Frances Lim

Managing Director, Global Macro and Asset Allocation and Portfolio Mgt of Strategic Partnerships

Max Lin

Partner and Director, Private Equity

Lucy Liu

Director, Client and Partner Group

Ming Lu

Partner and Co-Head of Asia Private Equity Business

Rony Ma

Director

Blaine MacDougald

Director and Co-head of Credit Research, Credit

Emily Mason

Principal, KKR Prisma

Kyle Matter

Director

Patrick Mattson

Managing Director

Kevin McMahon

Managing Director

Hilary McNamara

Director, Business Operations

David McNellis

Managing Director, Global Macro and Asset Allocation

Henry McVey

Partner and Head of Global Macro and Asset Allocation, CIO of KKR Balance Sheet

Ken Mehlman

Partner and Global Head of Public Affairs; Co-head KKR Global Impact

Jimmy Miele

Principal

George Mueller

Managing Director

Katherine T. B. de Mul

Director, Operations and Client Services

Narender Nanchary

Principal, Hedge Funds

Sanjay Nayar

CEO

William Needham

Managing Director

Sean Nelson

Director

Lesley Nurse

Director, Client and Partner Group

Scott Nuttall

Co-CEO

Ted Oberwager

Principal, Private Equity

Christian Ollig

Director, Private Equity

Timotheus Osnabrug

Director, Private Equity

John Park

Director, Private Equity

Chung Ho Park

Director, Private Equity

Vishal Patel

Managing Director

Clayton Perry

Managing Director, Client and Partner Group

Daniel Pietrzak

Partner

Samuel Plotner

Director

Jaka Prasetya

Partner

Sharath Reddy

Director, Credit

John Reed

Director, Credit

Janice Cook Roberts

Director, Client and Partner Group

Paul Roberts

Managing Director, KKR Prisma

James Rudy

Director, Principal Activities

Jean -Pierre Saad

Director, Private Equity

Matt Salem

Partner and Head of RE Credit

Kaveh Samie

Managing Director, Client and Partner Group

Richard Sarnoff

Managing Director

Kugan Sathiyanandarajah

Managing Director and Head of Healthcare Strategic Growth in Europe

Jeffrey Schachter

Managing Director

Lucian Schönefelder

Partner

Vance Serchuk

Managing Director, Americas Private Equity, Industrials Team

Stephen Shanley

Partner

Peggy Shaughnessy

Managing Director, Business Operations

Blake Shorthouse

Managing Director

Rob Siegel

Director, Information Technology

Tashwinder Singh

Director, Capital Markets

Duncan Smith

Principal, Credit

Pete Stavros

Co-Head of Global Private Equity

Chris Sun

Partner, Private Equity

Karan Swani

Director, Private Equity

Marta Szczerba

Director

Waldemar Szlezak

Managing Director

Weiyu Tan

Managing Director

Nate Taylor

Co-Head of Americas Private Equity

Paige Thacher

Principal

Cade Thompson

Partner, Capital Markets

Gaurav Trehan

Head of Asia Private Equity

Cecilio Velasco

Managing Director

Steven Wang

Principal, Private Equity

Douglas Watt

Managing Director

Joshua T. Weisenbeck

Partner

Dave Welsh

Partner and Head of Technology Growth Equity

Ryan L.G. Wilson

Managing Director

Alisa A. Wood

Partner

Angela Yang

Principal, Credit

Annie Yangeksakul

Principal, Hedge Funds

Eiji Yatagawa

Partner

Past deals in Medical Devices

Karo Healthcare

Acquisition in 2025
Karo Pharma is a pharmaceutical company. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.

HealthCare Global Enterprises

Acquisition in 2025
HealthCare Global Enterprises is a cancer center is a center which offers complete diagnosis and treatment radiation, surgical and medical oncology services under one a single roof. cancer care services. The also operate fertility clinics, multi-specialty hospitals providing cardiology, neurology, orthopedics, gastroenterology, urology, pulmonary and critical care services. Its service offerings comprise of the clinical lab, diagnosis, robotic surgery, bone marrow transplantation, and radiation oncology.

HealthCare Global

Acquisition in 2025
HealthCare Global they focuses on cancer care, tertiary care, infertility treatment, advanced screening, and diagnostics.

Henry Schein

Post in 2025
Henry Schein is a leading provider of healthcare products and services, primarily catering to office-based dental, medical, and animal health practitioners. The company operates through two main segments: healthcare distribution and technology & value-added services. In its healthcare distribution segment, Henry Schein combines global dental and medical businesses to distribute a wide range of consumable products, small equipment, laboratory supplies, and vitamins. The technology and value-added services segment focuses on offering practice management software and other technological solutions that enhance operational efficiency for healthcare professionals. With a strong emphasis on leveraging a network of people and technology, Henry Schein aims to support practitioners in delivering high-quality care.

Cortex

Private Equity Round in 2023
Cortex is creating an innovative, totally integrated, all-encompassing platform for assessing and treating AFib with precision, simplicity, and speed. The company has formed a proficient team comprising highly skilled and experienced engineers and clinical experts dedicated to introducing this innovative suite of technologies to the market.

Precipart

Private Equity Round in 2023
Precipart is a medical device company that offers motion control systems, ceramic injection molding, and micro manufacturing.

Bausch Health Companies

Post in 2023
Bausch Health Companies Inc. is a global specialty pharmaceutical, consumer health, and medical device company headquartered in Laval, Canada. It develops, manufactures, and markets a diverse range of products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four key segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment focuses on vision care, surgical, consumer, and ophthalmology products. The Salix segment is dedicated to gastroenterology products, while Ortho Dermatologics specializes in dermatological solutions. The Diversified Products segment includes pharmaceutical offerings in neurology and other therapeutic classes, alongside generic and dental products. Bausch Health is recognized as a market leader in consumer vision care in various regions, including India and China, and ranks among the top vision care companies in the United States.

Industrial Physics

Acquisition in 2023
Industrial Physics is manufacturer of test, measurement and inspection equipment focused on the food and beverage, metal cans, flexible packaging, paper and plastics, paint and coatings, medical device, materials testing and consumer electronics markets

Clinisupplies

Acquisition in 2022
Clinisupplies is a manufacturer and supplier of medical supplies focused on managing both acute and chronic conditions. The company's product range includes intermittent catheters, urinary sheaths, tubular support bandages, catheter valves, surgical tape, triangular bandages, and drainage bags. In addition to these medical supplies, Clinisupplies provides Clinidirect home delivery and clinical nursing services, which include drop-in clinics and home visits. Their nurses collaborate with NHS professionals to offer guidance on products, clinical education and training, and management of community spending, ensuring that patients receive comprehensive care and support.

Bettcher Industries

Acquisition in 2021
Bettcher Industries is an ISO 9001-certified manufacturing company established in 1944, known for its innovative equipment designed for the food processing, foodservice, industrial, and medical sectors. With over seventy years of experience, Bettcher Industries develops a wide range of products, including trimmers, weighing systems, food safety equipment, batter breading machines, pneumatic shears, electric gyro knives, and sharpening tools. These products enable food processing industries to efficiently transform raw materials into marketable food items while also providing solutions for industrial and medical applications that alleviate the discomfort associated with manual systems. The company serves a diverse global customer base, emphasizing quality and innovation in its manufacturing processes.

Sapphiros

Series A in 2021
Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.

PHC Holdings

Private Equity Round in 2021
PHC Holdings Corp is a global corporation dedicated to the development, manufacture, and sale of healthcare devices and services. Leveraging its expertise in consumer electronics and appliances, the company focuses on creating innovative healthcare and research technologies. By integrating ideas and advancements from its extensive network of industrial and consumer products, PHC Holdings aims to address significant global challenges in health and wellness. The company is recognized for delivering a comprehensive range of biomedical products that enhance healthcare delivery and improve patient outcomes.

Paige

Series C in 2021
Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.

Clinisupplies

Acquisition in 2020
Clinisupplies is a manufacturer and supplier of medical supplies focused on managing both acute and chronic conditions. The company's product range includes intermittent catheters, urinary sheaths, tubular support bandages, catheter valves, surgical tape, triangular bandages, and drainage bags. In addition to these medical supplies, Clinisupplies provides Clinidirect home delivery and clinical nursing services, which include drop-in clinics and home visits. Their nurses collaborate with NHS professionals to offer guidance on products, clinical education and training, and management of community spending, ensuring that patients receive comprehensive care and support.

J B Chemical & Pharmaceuticals

Acquisition in 2020
Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally. Today, JBCPL exports to over 30 countries across the world and earns more than half its revenue from its international business. JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. JBCPL has its headquarters in India’s financial capital, Mumbai. With a domestic sales force of 1,000 people, 17 internationally approved state of the art manufacturing units, a Research and Development Centre, and subsidiaries abroad, the organisation is continually enhancing value for its shareholders. In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.

Hetian Group

Acquisition in 2018
HeTian is a professional hospital management company specialized in operating and investing in integrated health care service providers. HeTian currently operates seven award-winning hospitals and health care centers focused on underserved Chinese cities. The company’s vision is to improve access to quality health care services by building a network of primary medical care providers supported by modern health care management best practices.

Ajax Health

Series B in 2018
Ajax Health is a private equity and venture capital firm established in 2017, with headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in all stages of a company's lifecycle, focusing on innovative medical device companies, medtech, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by investing in solutions that address significant challenges in the healthcare sector. Through its strategic investments, the firm seeks to foster advancements that improve patient outcomes and enhance care delivery.

Hyperion Materials & Technologies

Acquisition in 2017
Hyperion Materials & Technologies is a global provider of advanced materials, specializing in cemented carbide, diamond, and cubic boron nitride solutions. The company manufactures metal cutting and drilling equipment tailored for various industries, including aerospace, automotive, electronics, and medical sectors. By developing innovative tungsten carbide powders and wear-resistant tools, Hyperion enables its customers to enhance their business performance in demanding applications. The focus on hard and super-hard materials positions the company as a key player in the production of effective and durable components and tools.

EchoNous

Series B in 2017
EchoNous, Inc. is a medical device company based in Redmond, Washington, focused on developing advanced ultrasound systems that enhance bladder and kidney care. Incorporated in 2015, EchoNous specializes in point-of-care ultrasound (POCUS) applications, utilizing artificial intelligence and machine learning to improve diagnostic accuracy and efficiency. Its product lineup includes KOSMOS for cardiothoracic assessments, Vein for ultrasound-guided peripheral IV placement, and Uscan, an AI-driven tool for bladder assessment. The company aims to address common healthcare challenges by providing miniaturized ultrasound devices that streamline clinical workflows and enhance patient care, ultimately saving time and reducing costs for healthcare providers.

Laser Clinics Australia

Acquisition in 2017
Laser Clinics Australia now has clinics in over 80 convenient locations throughout Australia with many more to come. Since their first clinic opened in 2008 Laser Clinics Australia has established a dominant position in the cosmetic clinic market. They has carved a new niche, creating an exceptionally strong brand and large customer base through the supply of affordable, accessible and reliable cosmetic treatments.

Ajax Health

Series A in 2017
Ajax Health is a private equity and venture capital firm established in 2017, with headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in all stages of a company's lifecycle, focusing on innovative medical device companies, medtech, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by investing in solutions that address significant challenges in the healthcare sector. Through its strategic investments, the firm seeks to foster advancements that improve patient outcomes and enhance care delivery.

AcuFocus

Private Equity Round in 2016
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Spirox

Series C in 2016
Spirox, Inc., based in Menlo Park, California, is a medical device company focused on improving the quality of life for patients with nasal obstruction, particularly those suffering from nasal valve collapse (NVC). Formerly known as Nasoform, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive treatment option for this common yet often undertreated condition. The implant addresses weakened lateral wall cartilage, a significant contributor to nasal airway obstruction. Founded in 2011, Spirox aims to complete product development, secure marketing authorization in the United States, and initiate commercialization efforts to make their innovative solution available to patients. As of July 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.

EchoNous

Series A in 2015
EchoNous, Inc. is a medical device company based in Redmond, Washington, focused on developing advanced ultrasound systems that enhance bladder and kidney care. Incorporated in 2015, EchoNous specializes in point-of-care ultrasound (POCUS) applications, utilizing artificial intelligence and machine learning to improve diagnostic accuracy and efficiency. Its product lineup includes KOSMOS for cardiothoracic assessments, Vein for ultrasound-guided peripheral IV placement, and Uscan, an AI-driven tool for bladder assessment. The company aims to address common healthcare challenges by providing miniaturized ultrasound devices that streamline clinical workflows and enhance patient care, ultimately saving time and reducing costs for healthcare providers.

PHC Holdings

Funding Round in 2014
PHC Holdings Corp is a global corporation dedicated to the development, manufacture, and sale of healthcare devices and services. Leveraging its expertise in consumer electronics and appliances, the company focuses on creating innovative healthcare and research technologies. By integrating ideas and advancements from its extensive network of industrial and consumer products, PHC Holdings aims to address significant global challenges in health and wellness. The company is recognized for delivering a comprehensive range of biomedical products that enhance healthcare delivery and improve patient outcomes.

Gland Pharma

Private Equity Round in 2013
Gland Pharma Limited is a manufacturer and marketer specializing in injectable-focused generic liquid parenteral products. Established in 1978 in Hyderabad, India, the company has developed a diverse portfolio of key molecules, including heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections. Its product range spans various therapeutic categories such as anti-infectives, anesthetics, anti-coagulants, oncology, and more. Gland Pharma is particularly recognized for its expertise in small volume parenterals and has pioneered heparin technology in India, becoming a leader in glycosaminoglycans. The company primarily serves regulated markets, with a significant share of its business coming from the United States, Canada, Europe, and Australia. In addition to its manufacturing capabilities, Gland Pharma offers contract development and manufacturing services to global partners, reinforcing its commitment to high-quality injectable products. As of October 2017, Gland Pharma operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Apollo Hospitals

Post in 2013
Apollo Hospitals is widely recognized as the pioneer of private healthcare in India, and was the country’s first corporate hospital. The Apollo Hospitals Group, which started as a 150-bed hospital and today, operates 9200 beds across 64 hospitals. A forerunner in integrated healthcare, Apollo has a robust presence across the healthcare spectrum. The Group has emerged as the foremost integrated healthcare provider in Asia, with mature group companies that specialize in insurance, pharmacy, consultancy, clinics and many such key touch points of the ecosystem. The Apollo Group has touched the lives of over 45 million patients, from 121 countries.

Accellent

Acquisition in 2005
Accellent provide manufacturing services to the medical device industry in the cardiology, endoscopy and orthopaedic markets. Accellent has broad capabilities in precision component fabrication, finished device assembly, engineering support services and complete supply chain management. These capabilities enhance customers’ speed to market and return on investment by allowing companies to refocus internal resources more efficiently.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.